Algert Global LLC Kymera Therapeutics, Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Algert Global LLC holds 30,256 shares of KYMR stock, worth $1.28 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

30,256

Previous 32,706 7.49%

Holding current value

$1.28 Million

Previous $976,000 46.72%

% of portfolio

0.04%

Previous 0.03%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$30.16 - $52.4 $73,892 - $128,380	-2,450 Reduced 7.49%	30,256 $1.43 Million
Q2 2024 Aug 14, 2024	BUY	$29.85 - $39.42 $137,966 - $182,199	4,622 Added 16.46%	32,706 $976,000
Q1 2024 May 14, 2024	SELL	$22.9 - $43.57 $1.63 Million - $3.11 Million	-71,288 Reduced 71.74%	28,084 $1.13 Million
Q4 2023 Feb 14, 2024	SELL	$10.97 - $26.84 $319,885 - $782,654	-29,160 Reduced 22.69%	99,372 $2.53 Million
Q3 2023 Nov 13, 2023	BUY	$13.9 - $23.88 $1.01 Million - $1.74 Million	72,802 Added 130.63%	128,532 $1.79 Million
Q2 2023 Aug 14, 2023	BUY	$22.4 - $34.92 $1.25 Million - $1.95 Million	55,730 New	55,730 $1.28 Million
Q2 2022 Aug 15, 2022	SELL	$14.13 - $42.55 $116,459 - $350,697	-8,242 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$35.3 - $64.68 $126,762 - $232,265	3,591 Added 77.21%	8,242 $349,000
Q4 2021 Feb 14, 2022	BUY	$49.91 - $65.56 $21,960 - $28,846	440 Added 10.45%	4,651 $295,000
Q3 2021 Nov 15, 2021	BUY	$47.8 - $66.66 $201,285 - $280,705	4,211 New	4,211 $247,000

Others Institutions Holding KYMR

# of Institutions

184

Shares Held

64.4M

Call Options Held

50.6K

Put Options Held

81.7K

View Full List

About Kymera Therapeutics, Inc.

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.31B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

More about KYMR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Kymera Therapeutics, Inc. Transaction History